2010 October - 17 articles
Background: In 2005, bevacizumab was approved by Health Canada for patients with metastatic colorectal cancer (mcrc). Newfoundland and Labrador was one of the first Canadian provinces to fund this agent in combination with FOLFIRI (irinotecan, 5-fluo...
Purpose: Most male breast cancer tumours are hormone receptor–positive; the patients therefore receive endocrine therapy. There is, however, a paucity of published data on toxicities experienced by male breast cancer patients who are prescribed endoc...
Imagine a society in which patients are routinely euthanized—whether they want their lives to end or not—if their suffering cannot be alleviated without dulling their consciousness, eliminating their in-dependence, or threatening their di...
Purpose: Radiation-induced dermatitis is a common side effect of breast irradiation, with hypofractionation being a well-known risk factor. In the context of the widespread adoption of hypofractionated breast radiotherapy, we evaluated the effect of...
Interest has been increasing in the use of androgen deprivation therapy (adt) combined with radiation therapy (rt) in the management of localized prostate cancer. Preclinical studies have provided some rationale for the use of this combination. In pa...
In 1976, Peter Nowell, following observations of cytogenetic heterogeneity in a population of cancer-ous cells, proposed that this genetic diversity could be explained by hypothesizing that these cells are subject to evolutionary forces[...
After the discovery of the breast cancer–associated genes BRCA1 in 1994 and BRCA2 in 1995, genetic testing was introduced into clinical practice in North America and Europe[...]
Extramammary Paget disease (EMPD) is a rare skin disease commonly found in the anogenital region. In this study, we aimed to identify EMPD patients seen in the non-melanoma skin cancer clinic at Odette Cancer Centre and to describe the treatments del...
The words “personalized medicine” are used daily now in cancer care and research conversations. But what do those words really mean to us as patients, caregivers, physicians, managers of the health system, or researchers? Do we know how personalized...
Spindle-cell differentiation in ameloblastic carcinoma is a rare event. Although reported by many authors, it was first described as a separate entity in 1999 by Slater under the heading “low-grade spindle-cell ameloblastic carcinoma.” Here, we repor...
Extraskeletal myxoid chondrosarcoma (EMS) is a rare oncologic phenomenon characterized by chondroid and neurogenic differentiation in extraskeletal locations. These tumours represent fewer than 2.5% of all soft-tissue sarcomas and are most commonly f...
Defects in lipid metabolism have been found to be linked to several diseases, among which atherosclerosis, hypertension, obesity, and diabetes are the most important. Although cancer is chiefly a genetic disease, dietary lipid intake and metabolism a...
According to the published data, most primary central nervous system lymphomas (PCNSLS) are B-cell lymphomas; primary T-cell lymphomas are rare. In a search of the MEDLINE database, we found only 6 cases of primary T-cell PCNSL. Here, we present the...
Advanced hepatocellular carcinoma has a dismal prognosis, with a median overall survival of 7.9 months if untreated and of 10.7 months if treated with sorafenib. We present a case of advanced previously unresectable hepatocellular carcinoma in a 49-y...
A 60-year-old woman with breast cancer metastatic to the bones experienced no adverse skin reaction at the lumbar spine after a single 8-Gy photon-beam fraction prescribed to a depth of 5 cm. However, a subsequent treatment to the thoracic spine usin...
Multiple myeloma metastatic to the skin is a rare occurrence that usually reflects a high tumour burden. Here, we report the case of a woman with known multiple myeloma who developed cutaneous lesions on the right leg. Limited-field radiation treatme...
The opinions expressed in the abstracts are those of the authors and are not to be construed as the opinion of the publisher (Multimed Inc.), the organizers of the 2nd International Cancer Fatigue Symposium, or the University of Alberta, Faculty of N...
